[Human recombinant erythropoietin-alpha increases the efficacy of irradiation in preclinical model].
According to recent data erythropoietin receptor (EPOR) is expressed not only by bone marrow erythroid progenitors but by endothelial- and cancer cells and it was suggested that erythropoietin (EPO) may affect their functions as well. We have analyzed the effects of recombinant human erythropoietin-alpha (rHuEPOalpha) on radiation sensitivity of EPOR+ human epidermoid carcinoma (A431) xenograft model. In vivo rHuEPOalpha treatment was started after tumor cell inoculation into SCID mice. 5 Gy irradiation was performed on day 14, the effect of which was measured on day 22. Hemoglobin level, tumor-associated microvessels and HIF-1alpha expression of the xenograft were monitored during the experiment. rHuEPOalpha administration prevented the development of tumor-induced anemia of SCID mice and reduced the level of HIF-1alpha expression of the xenograft tumor without affecting tumor growth. We have found that rHuEPOalpha treatment significantly increased the efficacy of antitumor effect of irradiation which was partly mediated by complex effects on tumor-associated microvessels. In vitro rHuEPOalpha did not affect proliferation of A431 cells but enhanced the antiproliferative and proapoptotic effects of irradiation. We concluded that rHuEPOalpha administration positively modulated the antitumoral effects of irradiation at least by two pathways, decreasing systemic hypoxia resulting in decreased tumoral HIF-1alpha expression and enhancing direct effects on tumor-associated microvessels.
Lövey
József
J
Országos Onkológiai Intézet, Sugárterápiás, Budapest.
Kenessey
István
I
Rásó
Erzsébet
E
Dobos
Judit
J
Vágó
Agnes
A
Kásler
Miklós
M
Futosi
Krisztina
K
Döme
Balázs
B
Tímár
József
J
Tóvári
József
J
D000747:Anemia, Hypochromic / Q000209:etiology / Q000517:prevention & control; D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000098:blood supply* / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy*; D045744:Cell Line, Tumor; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000494:pharmacology*; D006397:Hematinics / Q000494:pharmacology*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D000860:Hypoxia / Q000378:metabolism / Q000517:prevention & control*; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D016513:Mice, SCID; D008833:Microcirculation / Q000528:radiation effects; D016133:Polymerase Chain Reaction; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*; D011994:Recombinant Proteins; D014183:Transplantation, Heterologous
D006397:Hematinics; D006454:Hemoglobins; C497443:Hif1a protein, mouse; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D011838:Radiation-Sensitizing Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa